Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2023
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer
Stephanie L Wethington, Payal D Shah, Lainie Martin, et al.
Nature Communications
|
August 1, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial
Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2026
Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies
Xiaolin Zhu, Edwin A Alvarez, Sarah E Umetsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Seung Tae Kim, Simon A Smith, Peter Mortimer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
Gynecologic Oncology
|
October 8, 2021
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
Payal D Shah, Stephanie L Wethington, Cheyenne Pagan, et al.
Blood Advances
|
June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML
Andrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
Nature Communications
|
August 12, 2024
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy
Emmanuel C Patin, Pablo Nenclares, Charleen Chan Wah Hak, et al.
The Journal of Clinical Investigation
|
November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
Magnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2023
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer
Stephanie L Wethington, Payal D Shah, Lainie Martin, et al.
Nature Communications
|
August 1, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial
Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2026
Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies
Xiaolin Zhu, Edwin A Alvarez, Sarah E Umetsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Seung Tae Kim, Simon A Smith, Peter Mortimer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
Gynecologic Oncology
|
October 8, 2021
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
Payal D Shah, Stephanie L Wethington, Cheyenne Pagan, et al.
Blood Advances
|
June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML
Andrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
Nature Communications
|
August 12, 2024
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy
Emmanuel C Patin, Pablo Nenclares, Charleen Chan Wah Hak, et al.
The Journal of Clinical Investigation
|
November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
Magnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.
Page
of 2